The battle of the pharmaceutical titans is getting spicy, and the vibes are off for Novo Nordisk. While Novo is out here trying to hype up its strategy for a post-Wegovy and Ozempic world, Eli Lilly is lowkey running up the score.
The Numbers Game
Real talk: investors aren't buying Novo’s roadmap. After the company’s Capital Markets Day, stock prices tanked because their growth targets were mid rather than market-leading. Meanwhile, Lilly is securing the bag. In the U.S., Lilly’s new oral weight loss pill, Foundayo, is grabbing one-third of new patients in the pill market and growing week by week. Even in the competitive Medicare space, Lilly is the main character; they’ve captured 70% of the 700,000 seniors who started GLP-1s since coverage kicked off in July.
Lilly currently holds about 61% of the U.S. GLP-1 market, leaving Novo with 39%. Analysts are betting on Lilly to keep the lead, pointing to their massive commercial firepower and a manufacturing edge. Because Foundayo is a small-molecule drug, it’s easier and cheaper to scale than Novo’s peptide-based Wegovy pill.
Novo’s Long Game
Novo isn’t folding just yet. They’re betting big on their pipeline, aiming to launch five potential blockbuster products by 2030 and hit $23 billion in sales by 2035. They’re hoping the upcoming launch of CagriSema—their combo drug—will help bridge the gap before patent expirations start hitting in the early 2030s. However, Wall Street is skeptical, especially since previous trial data for CagriSema was a bit of an L.
Why it matters
If you're looking at your portfolio or your side hustle, keep an eye on these drugmakers. GLP-1s are a gold mine, and Lilly's ability to scale manufacturing and dominate the Medicare scene is a major flex that’s currently winning the market war. Novo has to execute perfectly on their next wave of drugs, or they risk getting left in the dust.
